Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease

Table 3 Comparison between NAFLD patients with stage 0-2 fibrosis and those with stage 3 and 4 fibrosis (mean±SD).

	Stages 0-2 fibrosis	Stages 3,4 fibrosis	P value
Number	64	48
Age (yr)	47.8±14.5	54.3±14.0	0.02
Gender (female)	38 (59.4%)	38 (79.2%)	0.04
BMI	28.3±4.8	30.1±5.4	NS
Diabetes mellitus (%)	15 (23.4%)	19 (39.6%)	NS
Platelet count (±104/mL)	23.8±5.1	20.3±7.1	0.004
Prothrombin time (%)	96.9±11.1	90.1±14.7	0.018
Albumin (g/dL)	4.4±0.3	4.3±0.4	0.03
AST (IU/L)	67.0±37.5	87.9±51.2	0.02
ALT (IU/L)	113.1±65.2	116.3±67.9	NS
AST/ALT ratio	0.66±0.4	0.82±0.3	0.015
GGT (IU/L)	133.5±141.6	85.7±66.6	0.019
IgG (mg/dL)	1 408.1±367.0	1 555.5±446.4	NS
IgA (mg/dL)	316.3±172.3	371.0±133.5	NS
IgM (mg/dL)	137.2±79.1	163.8±64.9	NS
Type IV collagen 7S (ng/mL)	4.6±1.5	6.3±2.0	<0.001
Hyaluronic acid (ng/mL)	50.4±74.3	108.8±118.7	0.004
Fasting glucose (mg/dL)	115.1±49.4	116.6±43.1	NS
HbA1c (%)	5.6±1.2	6.4±1.9	0.01
Ferritin (ng/mL)	253.8±52.6	320.1±373.0	NS
FFA (mEq/L)	0.6±0.3	0.8±0.3	0.007
HOMA-R	5.7±5.8	5.8±4.6	NS